|
I know that generally hormone + patients have a more favorable prognosis than hormone negative, her2 + tumors are considered more aggressive than her2- and the majority of HER2+ patients are hormone negative. So if you are strongly er+ and pr+ and her2 3+, is this double good (two targets for treatment) or is this bad because of the er/her2 crosstalk?
I haven't seen any studies differentiating the her2+ population- except the er+/pr- tamoxifen study.
Yes, this is why we need a tumor registry to figure out all this stuff!
__________________
Are we there yet?
Dx 10/05 IDC, multi-focal, triple +, 5 nodes+
MRM, 4 DD A/C, 12 weekly taxol + herceptin
rads concurrent with taxol/herceptin
finished herceptin 01/08
ooph, Arimidex, bilateral DIEP reconstruction
NED
Univ. of WA, Seattle vaccine trial '07
|
Threaded Mode